| Entry |
|
|---|
| Name |
Lazertinib (USAN/INN) |
|---|
| Formula |
C30H34N8O3
|
|---|
| Exact mass |
554.2754
|
|---|
| Mol weight |
554.64
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03162 EGFR inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG03205): | D12245<US> |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Comment |
Treatment of non-small cell lung cancer (NSCLC)
|
|---|
| Target |
|
|---|
| Pathway |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01EB09 Lazertinib
D11980 Lazertinib (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03162 EGFR inhibitor
DG03205 Lazertinib
D11980 Lazertinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03205 Lazertinib
D11980 Lazertinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR* [HSA_VAR:1956v2]
D11980 Lazertinib (USAN/INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11980
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03162 EGFR inhibitor
DG03205 Lazertinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03205 Lazertinib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 41
1 C8x C 19.6000 -16.5200
2 C8y C 19.6000 -15.1200
3 C8y C 20.7900 -14.4200
4 C8x C 22.0500 -15.1200
5 C8y C 22.0500 -16.5200
6 C8y C 20.7900 -17.2200
7 N1y N 23.2400 -17.2200
8 N1b N 18.4100 -14.4200
9 O2a O 20.7900 -13.0200
10 C1x C 24.4300 -16.5200
11 C1x C 25.6900 -17.2200
12 O2x O 25.6900 -18.6200
13 C1x C 24.5000 -19.3200
14 C1x C 23.2400 -18.6200
15 N1b N 20.7900 -18.6200
16 C5a C 19.6000 -19.3200
17 C2b C 18.4100 -18.6200
18 O5a O 19.6000 -20.7200
19 C2a C 17.2200 -19.3200
20 C1a C 22.0024 -12.3200
21 C8y C 18.4100 -13.0200
22 N5x N 19.6224 -12.3200
23 C8x C 19.6224 -10.9200
24 C8x C 18.4100 -10.2200
25 C8y C 17.1976 -10.9200
26 N5x N 17.1976 -12.3200
27 N4y N 16.0021 -10.2296
28 N5x N 16.0060 -8.8202
29 C8y C 14.6699 -8.3811
30 C8y C 13.8394 -9.5161
31 C8x C 14.6622 -10.6566
32 C8y C 14.2506 -7.0741
33 C8x C 15.2062 -6.0202
34 C8x C 14.7782 -4.6872
35 C8x C 13.4098 -4.3914
36 C8x C 12.4542 -5.4453
37 C8x C 12.8822 -6.7783
38 C1b C 12.4600 -9.5114
39 N1c N 11.7522 -10.7279
40 C1a C 10.3601 -10.7232
41 C1a C 12.4424 -11.9324
BOND 45
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 2 8 1
9 3 9 1
10 7 10 1
11 10 11 1
12 11 12 1
13 12 13 1
14 13 14 1
15 7 14 1
16 6 15 1
17 15 16 1
18 16 17 1
19 16 18 2
20 17 19 2
21 9 20 1
22 8 21 1
23 21 22 2
24 22 23 1
25 23 24 2
26 24 25 1
27 25 26 2
28 21 26 1
29 25 27 1
30 27 28 1
31 28 29 2
32 29 30 1
33 30 31 2
34 27 31 1
35 29 32 1
36 32 33 2
37 33 34 1
38 34 35 2
39 35 36 1
40 36 37 2
41 32 37 1
42 30 38 1
43 38 39 1
44 39 40 1
45 39 41 1
|
|---|
